Determination of trimethylamine-N-oxide in combination with L-carnitine and γ-butyrobetaine in human plasma by UPLC/MS/MS.

An ultra-high-performance liquid chromatography-mass spectrometry (UPLC/MS/MS) method was developed and validated for the quantification of trimethylamine-N-oxide (TMAO) simultaneously with TMAO-related molecules L-carnitine and γ-butyrobetaine (GBB) in human blood plasma. The separation of analytes was achieved using a Hydrophilic interaction liquid chromatography (HILIC)-type column with ammonium acetate-acetonitrile as the mobile phase. TMAO determination was validated according to valid US Food and Drug Administration guidelines. The developed method was successfully applied to plasma samples from healthy volunteers.

[1]  S. Hazen,et al.  γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. , 2014, Cell metabolism.

[2]  E. Liepinsh,et al.  Risks and benefits of carnitine supplementation in diabetes. , 2014, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[3]  E. Liepinsh,et al.  Selective inhibition of OCTN2 is more effective than inhibition of gamma-butyrobetaine dioxygenase to decrease the availability of l-carnitine and to reduce myocardial infarct size. , 2014, Pharmacological research.

[4]  S. Hazen,et al.  Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. , 2014, Analytical biochemistry.

[5]  G. Lopaschuk,et al.  Gut microbiota metabolism of L-carnitine and cardiovascular risk. , 2013, Atherosclerosis.

[6]  R. Petrovska,et al.  Meldonium decreases the diet‐increased plasma levels of trimethylamine N‐oxide, a metabolite associated with atherosclerosis , 2013, Journal of clinical pharmacology.

[7]  J. DiNicolantonio,et al.  L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. , 2013, Mayo Clinic proceedings.

[8]  F. Bushman,et al.  Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013, Nature Medicine.

[9]  I. Konrāde,et al.  Mildronate treatment alters γ‐butyrobetaine and l‐carnitine concentrations in healthy volunteers , 2011, The Journal of pharmacy and pharmacology.

[10]  Brian J. Bennett,et al.  Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease , 2011, Nature.

[11]  A. Lesimple,et al.  Measurement of urinary trimethylamine and trimethylamime oxide by direct infusion electrospray quadrupole time-of-flight mass spectrometry. , 2010, Analytical biochemistry.

[12]  U. Spiekerkoetter,et al.  ESI-MS/MS measurement of free carnitine and its precursor γ-butyrobetaine in plasma and dried blood spots from patients with organic acidurias and fatty acid oxidation disorders. , 2010, Molecular genetics and metabolism.

[13]  Sangkyun Lee,et al.  Determination of Urinary Trimethylamine and Trimethylamine N-oxide by Liquid Chromatography-Tandem Mass Spectrometry Using Mixed-Mode Stationary Phases , 2010 .

[14]  K. Eder,et al.  Determination of carnitine, its short chain acyl esters and metabolic precursors trimethyllysine and gamma-butyrobetaine by quasi-solid phase extraction and MS/MS detection. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  R. Milne,et al.  Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  T. Annesley.  Ion suppression in mass spectrometry. , 2003, Clinical chemistry.

[17]  H. Nakajima,et al.  Measurement of carnitine precursors, ε-trimethyllysine and γ-butyrobetaine in human serum by tandem mass spectrometry , 1999 .

[18]  E. Lukevics,,et al.  Betaines derived from amino and hydrazino acids as phase transfer catalysts , 1990 .